10.35
price up icon16.95%   1.50
pre-market  プレマーケット:  10.68   0.33   +3.19%
loading
前日終値:
$8.85
開ける:
$9.15
24時間の取引高:
2.32M
Relative Volume:
2.11
時価総額:
$519.16M
収益:
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.9677
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
+6.59%
1か月 パフォーマンス:
-0.48%
6か月 パフォーマンス:
+3.50%
1年 パフォーマンス:
-27.87%
1日の値動き範囲:
Value
$9.15
$11.00
1週間の範囲:
Value
$8.22
$11.00
52週間の値動き範囲:
Value
$5.035
$15.36

Regenxbio Inc Stock (RGNX) Company Profile

Name
名前
Regenxbio Inc
Name
セクター
Healthcare (1166)
Name
電話
240-552-8181
Name
住所
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
職員
353
Name
Twitter
@REGENXBIO
Name
次回の収益日
2025-03-04
Name
最新のSEC提出書
Name
RGNX's Discussions on Twitter

RGNX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RGNX
Regenxbio Inc
10.35 454.95M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-11 ダウングレード Goldman Buy → Neutral
2025-02-07 再開されました Raymond James Outperform
2024-11-15 再開されました Morgan Stanley Overweight
2024-10-10 再開されました Raymond James Outperform
2024-06-07 開始されました Goldman Buy
2024-03-11 開始されました H.C. Wainwright Buy
2024-03-08 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-03-06 アップグレード Leerink Partners Market Perform → Outperform
2024-02-21 再開されました Raymond James Outperform
2023-11-01 開始されました Stifel Buy
2023-06-02 開始されました Robert W. Baird Outperform
2022-06-23 開始されました Berenberg Buy
2021-12-15 開始されました Wedbush Neutral
2021-10-19 再開されました Morgan Stanley Overweight
2021-01-06 アップグレード Raymond James Outperform → Strong Buy
2020-12-16 開始されました UBS Buy
2020-06-25 再開されました BofA/Merrill Buy
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2019-08-20 アップグレード SVB Leerink Underperform → Mkt Perform
2019-06-18 繰り返されました Chardan Capital Markets Buy
2019-06-14 再開されました Raymond James Outperform
2019-06-05 繰り返されました Chardan Capital Markets Buy
2019-02-25 アップグレード Evercore ISI In-line → Outperform
2019-02-05 アップグレード Raymond James Outperform → Strong Buy
2018-12-17 繰り返されました Chardan Capital Markets Buy
2018-11-08 繰り返されました BofA/Merrill Neutral
2018-08-08 繰り返されました Chardan Capital Markets Buy
2018-07-23 ダウングレード BofA/Merrill Buy → Neutral
2018-07-10 繰り返されました Chardan Capital Markets Buy
2018-05-09 繰り返されました Barclays Overweight
2018-04-09 繰り返されました Chardan Capital Markets Buy
2018-03-12 ダウングレード Evercore ISI Outperform → In-line
2018-02-13 開始されました Mizuho Neutral
2017-11-09 再開されました Morgan Stanley Overweight
すべてを表示

Regenxbio Inc (RGNX) 最新ニュース

pulisher
Jun 02, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - Citizen Tribune

Jun 02, 2025
pulisher
Jun 02, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data fro - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

New Duchenne Muscular Dystrophy Treatment Data: REGENXBIO to Reveal Key Trial Results June 5 - Stock Titan

Jun 02, 2025
pulisher
May 27, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

May 27, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia

May 26, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa

May 26, 2025
pulisher
May 22, 2025

REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle

May 22, 2025
pulisher
May 21, 2025

Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.

May 21, 2025
pulisher
May 20, 2025

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Stifel maintains Buy on Regenxbio, price target at $40 By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

Stifel maintains Buy on Regenxbio, price target at $40 - Investing.com

May 20, 2025
pulisher
May 20, 2025

Regenxbio Secures $250 Million In New Royalty Bonds - Finimize

May 20, 2025
pulisher
May 19, 2025

REGENXBIO secures $150 million to extend cash runway By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutiv - GuruFocus

May 19, 2025
pulisher
May 19, 2025

REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding - GuruFocus

May 19, 2025
pulisher
May 19, 2025

REGENXBIO secures $150 million to extend cash runway - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

RegenXBio Secures $250M Royalty Monetization Deal - TipRanks

May 19, 2025
pulisher
May 19, 2025

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - Eagle-Tribune

May 19, 2025
pulisher
May 19, 2025

Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

REGENXBIO's $250M Royalty Deal Extends Cash Runway to 2027, Funds Multiple Late-Stage Programs - Stock Titan

May 19, 2025
pulisher
May 16, 2025

Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN

May 16, 2025
pulisher
May 15, 2025

REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year - TipRanks

May 15, 2025
pulisher
May 15, 2025

REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA - CGTLive®

May 15, 2025
pulisher
May 15, 2025

REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next - simplywall.st

May 15, 2025
pulisher
May 14, 2025

Regenxbio BLA for Hunter syndrome candidate accepted by FDA - MSN

May 14, 2025
pulisher
May 14, 2025

(RGNX) Proactive Strategies - news.stocktradersdaily.com

May 14, 2025
pulisher
May 14, 2025

Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy fo - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - Eastern Progress

May 14, 2025
pulisher
May 14, 2025

US FDA accepts Regenxbio’s application for MPS II gene therapy - World Pharmaceutical Frontiers

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Stifel maintains buy on Regenxbio, reiterates $40 target By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Nigeria

May 13, 2025

Regenxbio Inc (RGNX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
大文字化:     |  ボリューム (24 時間):